Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Blood (2014) 123 (3): 317–325.

https://doi.org/10.1182/blood-2013-10-529974

Published: 2014

Includes: Supplemental data

Journal Articles

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

John Pasi, MBChB, PhD, FRCP, FRCPath, James Potts, Ph.D, MPH, Shuanglian Li, Ph.D., Ping Wang, Ph.D., Sarah Kulke, M.D., Glenn F Pierce, MD, PhD, Haiyan Jiang, PhD

Blood (2013) 122 (21): 3590.

https://doi.org/10.1182/blood.V122.21.3590.3590

Published: 2013

Journal Articles

Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

Kathelijn Fischer, MD, PhD, Roshni Kulkarni, MD, Myles Bradbury, MD, Margaret V. Ragni, MD, MPH, Savita Rangarajan, MBBS, FRCP, FRCPath, Yingwen Dong, PhD, Shuanglian Li, MD, PhD, Haiyan Jiang, PhD, Karen Nugent, MSc, Glenn F Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 3599.

https://doi.org/10.1182/blood.V122.21.3599.3599

Published: 2013

Journal Articles

Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein

Amy Shapiro, MD, James Potts, Ph.D, MPH, Shuanglian Li, Ph.D., Leonard A. Valentino, MD, FAAP, Lei Diao, PhD, Ping Wang, Ph.D., Brian Robinson, M.D., Glenn F Pierce, MD, PhD, Haiyan Jiang, PhD

Blood (2013) 122 (21): 2349.

https://doi.org/10.1182/blood.V122.21.2349.2349

Published: 2013

Journal Articles

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Amy Shapiro, MD, John Pasi, MBChB, PhD, FRCP, FRCPath, Johnny Mahlangu, MD, David J. Perry, MD, PhD, FRCP, FRCPath, Jerry S Powell, MD, Margaret V. Ragni, MD, MPH, Leonard A. Valentino, MD, FAAP, Margareth Ozelo, MD, PhD, Karen Nugent, MSc, Shuanglian Li, MD, PhD, Aoife Brennan, MB, BCh, BAO, MMSC, Glenn F Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 2350.

https://doi.org/10.1182/blood.V122.21.2350.2350

Published: 2013

NARROW

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Email alerts

ASH Publications

American Society of Hematology

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only